Literature DB >> 9652301

Induction of tolerance via the respiratory mucosa.

J L Lowrey1, N D Savage, D Palliser, M Corsin-Jimenez, L M Forsyth, G Hall, S Lindey, G A Stewart, K A Tan, G F Hoyne, J R Lamb.   

Abstract

Immunological tolerance is defined as a state of specific non-responsiveness to a particular antigen induced by previous exposure to that same antigen. The mucosal surfaces comprise the upper and lower respiratory tracts, the gastrointestinal tract and the urogenitary tract, and are a major site of antigenic challenge. The immune system associated with the mucosa has the extraordinary potential to discriminate between antigens that are harmless (e.g. inhaled and dietary antigens) and those that are associated with pathogens. Normally soluble proteins delivered through the mucosal surfaces do not elicit a strong systemic immune response but instead induce a transient local immune response that is replaced by long-term peripheral unresponsiveness this is termed mucosal tolerance. The phenomenon of oral tolerance is well established and considerable attention has focussed on defining the underlying mechanisms. However, only comparatively recently was the induction of tolerance via the respiratory mucosa described, and it is this form of mucosal tolerance which forms the basis of this review.

Entities:  

Mesh:

Year:  1998        PMID: 9652301     DOI: 10.1159/000023931

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  9 in total

1.  Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy.

Authors:  A D Dick; V Sharma; J Liversidge
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

2.  Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.

Authors:  H Bakke; K Lie; I L Haugen; G E Korsvold; E A Høiby; L M Naess; J Holst; I S Aaberge; F Oftung; B Haneberg
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Are we getting enough allergens?

Authors:  Allan Linneberg
Journal:  Int Arch Allergy Immunol       Date:  2008-06-03       Impact factor: 2.749

4.  Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy.

Authors:  Birgit Winkler; Caroline Bolwig; Ulla Seppälä; Michael D Spangfort; Christof Ebner; Ursula Wiedermann
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

5.  DGKα DNA vaccine relieves airway allergic inflammation in asthma model possibly via induction of T cell anergy.

Authors:  Yan Wang; Qiao Zhang; Qianli Ma; Youlan Zhang; Zhiwei Li; Changzheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

6.  Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.

Authors:  D G Millar; T R Hirst; D P Snider
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 7.  Age-related changes in ocular mucosal tolerance: Lessons learned from gut and respiratory tract immunity.

Authors:  Jeremias G Galletti; Cintia S de Paiva
Journal:  Immunology       Date:  2021-05-02       Impact factor: 7.215

Review 8.  Immune development and intestinal microbiota in celiac disease.

Authors:  Tamara Pozo-Rubio; Marta Olivares; Esther Nova; Giada De Palma; Jorge R Mujico; Maria Desamparados Ferrer; Ascensión Marcos; Yolanda Sanz
Journal:  Clin Dev Immunol       Date:  2012-09-11

9.  Therapeutical measures to control airway tolerance in asthma and lung cancer.

Authors:  Katerina Andreev; Anna Graser; Anja Maier; Stephanie Mousset; Susetta Finotto
Journal:  Front Immunol       Date:  2012-07-26       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.